文献速递前列腺癌

系统穿刺与融合穿刺前列腺活检的患者体验比较

Patient Experience of Systematic Versus Fusion Prostate Biopsies.
PubMed 文献 · Eur Urol Oncol · 2018-05-15

一项前瞻性试验纳入262例男性患者,203例接受经直肠系统12针超声引导活检(SBx),59例接受磁共振成像/超声融合引导活检(FBx),活检后即刻和30天填写问卷。FBx组30天内疼痛和血尿比例低于SBx组,但两组不适评分中位数无差异。愿意再次活检者即刻疼痛和不适评分更低。

要点

  • FBx组30天内疼痛比例低于SBx组(20% vs 34%,p=0.043)。
  • FBx组血尿比例低于SBx组(44% vs 69%,p<0.001)。
  • 愿意再次活检者即刻NRS疼痛和不适评分均低于不愿意者。

核心结论

  • FBx在活检后30天内与较少的疼痛和血尿相关,相比SBx。

研究设计与样本

  • 前瞻性试验纳入262例男性患者,203例接受经直肠SBx,59例接受FBx,2015-2016年在赫尔辛基大学医院进行。

主要发现

  • SBx组和FBx组每例患者穿刺针数中位数分别为12针和3针。
  • 30天时SBx组经历疼痛的患者比例高于FBx组(70/203 [34%] vs 12/59 [20%];p=0.043),而不适评分中位数无差异。
  • FBx组血尿较少见(26/59 [44%] vs 140/203 [69%];p<0.001)。
  • 活检后即刻愿意再次活检的患者报告较低的NRS中位数(3.0 [四分位距2.0-5.0] vs 5.0 [4.3-6.0];p<0.001)和不适评分(4.0 [2.0-6.0] vs 7.0 [5.0-8.0];p<0.001),相比不愿意者。
  • 30天时,愿意再次活检的患者经历较少不适(2.0 [四分位距1.0-2.0] vs 2.0 [2.0-3.0];p=0.008)和发热(6/195 [3.1%] vs 6/28 [22%];p=0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 非随机设计是局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The magnetic resonance imaging/ultrasound fusion-guided biopsy (FBx) technique has gained popularity in prostate cancer (PCa) diagnostics, but little is known about its effect on patient experience. OBJECTIVE: To evaluate pain, discomfort and other non-infectious complications in PCa patients undergoing either systematic 12-core transrectal ultrasound-guided biopsy (SBx) or FBx and patient willingness to undergo rebiopsy. DESIGN, SETTING, AND PARTICIPANTS: A prospective trial of 262 male patients, 203 of whom underwent transrectal SBx and 59 FBx at Helsinki University Hospital in 2015-2016. Patients completed two questionnaires immediately after and at 30 d after biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: Patients reported pain and discomfort on a numeric rating scale (NRS; 0-10) immediately after biopsy. At 30 d, discomfort was measured on a scale ranging from 1 (no inconvenience) to 4 (maximal inconvenience). Other symptoms were reported dichotomously (yes/no) in both questionnaires. Mann-Whitney U, Pearson's χ2, and logistic regression tests were used. RESULTS AND LIMITATIONS: For the SBx and FBx groups the median number of cores per patient was 12 and three, respectively. At 30 d, a higher proportion of patients in the SBx group had experienced pain than in the FBx group (70/203 [34%] vs 12/59 [20%]; p=0.043), whereas there was no difference in the median discomfort scores. Hematuria was less common in the FBx group (26/59 [44%] vs 140/203 [69%]; p<0.001). Patients willing to undergo rebiopsy immediately post-biopsy reported lower median NRS (3.0 [interquartile range 2.0-5.0] vs 5.0 [4.3-6.0]; p<0.001) and discomfort scores (4.0 [2.0-6.0] vs 7.0 [5.0-8.0]; p<0.001) than those unwilling. At 30 d, less discomfort (2.0 [interquartile range 1.0-2.0] vs 2.0 [2.0-3.0]; p=0.008) and fever (6/195 [3.1%] vs 6/28 [22%]; p=0.001) were experienced by patients willing to undergo rebiopsy. The nonrandomized design was a limitation. CONCLUSIONS: FBx is associated with less pain and hematuria than SBx during the 30-d interval after biopsy. PATIENT SUMMARY: Magnetic resonance imaging (MRI)-targeted prostate biopsy is associated with less pain, discomfort, and blood in the urine compared to the standard ultrasound-guided procedure. Performing MRI-targeted procedures may reduce biopsy-related complications and promote adherence to recommended repeat biopsy for patients on active surveillance for prostate cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Eineluoto JT, Järvinen P, Kilpeläinen T, et al. Patient Experience of Systematic Versus Fusion Prostate Biopsies. Eur Urol Oncol. 2018. PMID: 31102622. doi:10.1016/j.euo.2018.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。